STAT+: Pharmalittle: Merck sues U.S. to halt Medicare drug-price negotiation; FDA oncology head wants advisory panels to keep voting on new drugs
Rise and shine, everyone, another busy day is on the way. We can tell by…
Category: Pharma
STAT+: The woman behind AstraZeneca’s cancer winning streak
CHICAGO — It was the kind of moment scientists who develop new medicines wait their…
STAT+: FDA removes neurologist with financial ties to Eisai and Biogen from Alzheimer’s advisory panel
The Food and Drug Administration has removed a neurologist with financial ties to Biogen and…
STAT+: FDA oncology head wants advisory panels to keep voting on new drugs
CHICAGO — As commissioner of the Food and Drug Administration, Robert Califf has made clear…
STAT+: Pharmalittle: AstraZeneca lung cancer drug halves death risk; 400 Grail patients incorrectly told they may have cancer
Good morning, everyone, and welcome to another working week. We hope the weekend respite was…
.jpg)
STAT+: To push antibiotic makers to be more green, a new system will certify manufacturing practices
In response to concerns about pollution caused by antibiotic production, an industry group is launching…
STAT+: Keytruda’s benefits, a breast cancer win, the ‘dom-zim doublet’: Weekend wrap-up from ASCO
CHICAGO — The annual meeting of the American Society of Clinical Oncology is back in…
STAT+: Biotechs face challenges as the industry’s annual bash returns to Boston
The world has changed since 2018 when the Biotechnology Innovation Organization last brought its annual…
STAT+: Immunogen drug prolongs survival of women with advanced ovarian cancer
CHICAGO — An antibody that delivers chemotherapy directly to tumor cells extended the lives of…
STAT+: Pharmalittle: Medicare holds firm on Alzheimer’s drug coverage policy; Pfizer says antibiotic combo can treat some superbugs
And so, another working week will soon draw to a close. Not a moment too…
Insurance alone didn’t guarantee adherence to Ozempic, study finds
Having insurance coverage alone doesn’t guarantee that people can afford or would be willing to…
STAT+: Pharmalittle: Coherus undercuts AbbVie with discounted Humira; FDA approves second RSV vaccine
Good morning, everyone. Damian Garde here, filling in for Ed Silverman on the back half…
STAT+: Coherus works with Mark Cuban to sell biosimilar Humira at steep discounts
In a bold move, Coherus BioSciences plans to sell a biosimilar version of Humira —…
STAT+: CVS warns PBM reforms ‘could lead to higher costs’
As Congress considers wide-ranging reforms to pharmacy benefit managers, a top executive at CVS Health,…
STAT+: Pharmalittle: Appeals court rules Purdue can shield Sacklers from lawsuits; chemo shortage blamed on drugmakers’ lack of investment
Hey there. STAT reporter Andrew Joseph here welcoming you to Wednesday’s edition of Pharmalittle, with…
Sacklers win appeal that shields them from opioid lawsuits, clearing way for bankruptcy settlement
A federal appeals court ruled Tuesday Purdue Pharma can shield its owners — members of…
STAT+: Pharmalittle: Pfizer touts study data for hemophilia drug; former Novartis execs cleared of bribery in Greece
Good morning, everyone, and how are you today? We are doing find, thank you, especially…
STAT+: Pharmalittle: EMA urges revoking authorization for Novartis sickle cell drug; U.K. tries to placate pharma execs
And so, another working week will soon draw to a close. Not a moment too…
Opinion: STAT+: An overlooked way to make participants in clinical trials look more like America
A recent report from the National Academies of Sciences, Engineering and Medicine (of which one…
STAT+: Bristol drug reduces reliance on transfusions for people with chronic blood disorder
In a study reported Thursday, a medicine from Bristol Myers Squibb nearly doubled the treatment…
STAT+: Gilead and Teva defend antitrust claims that prices for HIV medicines were unfairly kept high
Amid concern that HIV prevention pills are not being widely taken by those at highest…
STAT+: Pharmalittle: FDA approvals will stop if U.S. defaults on its debts; DEA failed to punish wholesaler blamed in opioid crisis
Oh, what a beautiful morning. Yes, this is a cliché, but the saying is apt,…
STAT+: Pharmalittle: Biden administration proposes yearly audit for costliest Medicaid drugs; few at high risk of HIV take prevention pills
Top of the morning to you. The middle of the week is upon us and,…
STAT+: Congress highlighted a chemo drug’s price to blast PBMs — but it’s not a PBM issue
WASHINGTON — Congress blasted drug middlemen at a hearing Tuesday, with multiple lawmakers pointing to…
STAT+: Pharmalittle: Pfizer and Novo disclose upbeat data on oral weight loss drugs; PBM trade group blasts House committee over hearing
Rise and shine, another busy day is on the way. We can tell because the…
FDA budget battles, prisons’ sobering Covid response & BIO’s CEO search is on
You’re reading the web edition of D.C. Diagnosis. Sign up here to receive this newsletter…
STAT+: Seagen criticized by shareholder advisory firm for ‘problematic’ executive compensation ahead of Pfizer acquisition
As Seagen prepares to be acquired by Pfizer, an investor advisory firm is raising concerns…
Novo says oral version of Ozempic leads to 15% weight loss
An oral version of semaglutide, the drug marketed as Ozempic and Wegovy, led to dramatic…
STAT+: Pharmalittle: Many employer health plans won’t pay for obesity drugs; FDA panel rejects Intercept NASH drug
Good morning, everyone, and welcome to another working week. We hope the weekend respite was…
STAT+: In early trial, drug appears to reduce harmful protein buildup in heart
An early-stage drug for a heart disease called ATTR-CM showed potential to reverse disease progression,…
STAT+: Study: 1 in 5 primary endpoints changed in late-stage trials of cancer drugs already underway
Amid increased concerns over a lack of transparency in clinical trials, a new study found…
STAT+: Novo Nordisk pauses ads for weight loss drug Wegovy as it struggles to meet demand
Novo Nordisk is pausing ads for its obesity drug Wegovy as it struggles to keep…
STAT+: FDA official offers insights into whether gene therapy makers could use common manufacturing process
WASHINGTON — A Food and Drug Administration official provided some insights this week into the…
STAT+: Pharmalittle: AstraZeneca plans to ‘love’ China’s Communist Party; U.S. Supreme Court rules against Amgen in patent case
And so, another working week will soon draw to a close. Not a moment too…
Opinion: How I helped Pfizer think through the ethics of Viagra 25 years ago
Twenty-five years ago, 75-year-old Bob Dole — former Republican presidential candidate and U.S. senator from…
After new cluster, health officials warn mpox could resurge this summer
Federal health officials warned Thursday that there was a significant risk the mpox virus will…
STAT+: Supreme Court rules against Amgen in closely watched case over scope of patent claims
In a case that had the pharmaceutical industry on edge, the U.S. Supreme Court upheld…
STAT+: Pharmalittle: Appellate judges appear skeptical of FDA decisions on abortion pill; FTC widens probe into PBMs
Top of the morning to you, and a fine one it is. Once again, crystal…
STAT+: FTC widens probe into pharmacy benefit managers to include group purchasing organizations
The Federal Trade Commission is widening its probe into pharmacy benefit managers and their impact…
STAT+: Could an upcoming Supreme Court case make the FDA slower?
WASHINGTON — The Food and Drug Administration could take longer to write regulations and make…
STAT+: Pharmalittle: FTC suit over Amgen spotlights ‘bundling’ deals with insurers; FDA staff says Pfizer RSV vaccine is effective
Rise and shine, everyone. The middle of the week is upon us. Have heart, though….
STAT+: FTC move to block the Amgen-Horizon deal highlights concerns over negotiations with insurers
In an unexpected move, the U.S. Federal Trade Commission on Tuesday filed a lawsuit to…
AstraZeneca is third member to leave PhRMA in five months
WASHINGTON — AstraZeneca has decided to leave the brand drug lobbying powerhouse PhRMA halfway through…
STAT+: Pharmalittle: FTC may sue to block Amgen deal for Horizon; Supreme Court declines Teva appeal on skinny labeling
Oh, what a beautiful morning! Pardon the cliché, but crystal clear blue skies and deliciously…
Opinion: The U.S. needs to pressure India to improve drug safety
On Feb. 2, the Food & Drug Administration issued an alert warning about “Made in…
Opinion: A breakthrough drug will require big changes for eye care doctors
Advancement in the science of eye care over the past 10 years has led to…
STAT+: U.S. Supreme Court declines to hear ‘skinny labeling’ case with implications for generic drug access
After months of anticipation, the U.S. Supreme Court declined to hear an appeal of a…
STAT+: Pharmalittle: FDA OKs new kind of drug to treat hot flashes; Alzheimer’s drug could cost Medicare up to $5 billion a year
Good morning, everyone, and welcome to another working week. We hope the weekend respite was…
Opinion: Compounding pharmacies offer a fix for shortages of essential drugs
In the early days of the Covid pandemic, gravely ill patients began to fill America’s…
STAT+: Pharmalittle: U.S. Senate committee passes PBM bills; Pfizer CEO predicts pharma will sue over Medicare price negotiations
And so, another working week will soon draw to a close. Not a moment too…